Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows

Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, according to data shared with Reuters by Hazeltree.

Reuters • Feb 13, 2026

US could take action including fines against Hims after brief Wegovy copy launch

The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, attorneys and other experts told Reuters.

Reuters • Feb 13, 2026

A Historic Opportunity For Dividend Investors To Win Big

AI panic crushed SaaS and dragged down BDCs and asset managers. Trading at steep discounts and high dividend yields, we think that this is a historic opportunity. We explain why the market got it wrong and highlight rare opportunities to potentially win big.

Seeking Alpha • Feb 13, 2026

Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More

Traders targeting heavily shorted stocks are looking to play one of two sides: betting on a company's downfall or hunting for a short squeeze.

Benzinga • Feb 13, 2026

Hims & Hers Strengthens Integrated Personalized Digital Care Platform

HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.

Zacks Investment Research • Feb 12, 2026

HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?

Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.

Zacks Investment Research • Feb 11, 2026

HIMS Selloff Creates De-Risked Entry

HIMS Selloff Creates De-Risked Entry

Seeking Alpha • Feb 11, 2026

Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing

Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit against Hims over alleged obesity drug copycats.

Bloomberg Markets and Finance • Feb 11, 2026

Novo says it's suing Hims to stop obesity drug copycats

Novo Nordisk Chief Executive Officer Maziar Mike Doustdar says it's suing Hims & Hers for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Read more here: https://bloom.bg/4tuKb6f

Bloomberg Markets and Finance • Feb 11, 2026

Why Hims Stock Slid 40% In A Month?

There are two words that can cause a stock to plummet quicker than one can utter semaglutide: FDA warning. This is precisely what transpired with Hims & Hers Health Inc's shares, as Hims & Hers stock (NYSE: HIMS) dropped approximately 34% over the past month due to investor panic triggered by regulatory scrutiny and increasing legal issues.

Forbes • Feb 10, 2026